Five Things Facing Teva's New CEO Richard Francis :: Generics Bulletin
Restasis (cyclosporine): Side effects, dosage, and more
Allergan settles with one of four companies contesting Restasis patent | Reuters
Cyclosporine (Restasis): Uses, Side Effects, Dosage & Reviews
FDA Approves Restasis Generic for Dry Eye - GoodRx
FDA Fires Back Over Teva Suit on Restasis 180 Days of Exclusivity | RAPS
Generic Restasis Availability - Drugs.com
Mylan: Did The FDA Clear The Runway For Generic Restasis? (NASDAQ:VTRS) | Seeking Alpha
Teva Gets a Head Start Over Rivals With Launch of HIV Generics; Analyst Says 'Buy'
FDA Issues Contamination Warnings for Two MSM Eye Drops - Eyewire+
Teva Canada Announces the Launch of Teva-Cyclosporine® Ophthalmic Emulsion, the First Generic Version of Restasis® in Canada for the Treatment of Dry Eye Disease
Teva - Pharma
FDA Approves First Generic Formulation of Restasis - Eyewire+
Teva
Restasis Coupon, Cost & Discount Savings - PricePro Pharmacy
Controversy Over Restasis Patents is Misplaced - IPWatchdog.com | Patents & Intellectual Property Law
Xiidra vs. Restasis: Differences, similarities, and which is better for you
Court throws out Allergan's patent deal with Native American tribe - PMLiVE
FDA Approves Restasis Generic for Dry Eye - GoodRx
US federal judge invalidates Allergan patents on Restasis - Pharmaceutical Business review
In a New Twist in Restasis Legal Battle, Teva Sues the FDA
Dear Cyclosporine ANDA Applicants Letter
Restasis: Why US consumers paid billions for drug deemed ineffective in other countries
